Phibro Animal Health Corporation
$ 51.89
-0.50%
04 Mar - close price
- Market Cap 2,103,346,000 USD
- Current Price $ 51.89
- High / Low $ 53.01 / 51.58
- Stock P/E 22.96
- Book Value 8.20
- EPS 2.26
- Next Earning Report 2026-05-13
- Dividend Per Share $0.48
- Dividend Yield 0.92 %
- Next Dividend Date 2026-03-25
- ROA 0.08 %
- ROE 0.32 %
- 52 Week High 56.17
- 52 Week Low 15.95
About
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Analyst Target Price
$48.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-27 | 2025-05-06 | 2025-02-05 | 2024-11-06 | 2024-08-28 | 2024-05-08 | 2024-02-07 | 2023-11-08 | 2023-08-30 | 2023-05-03 |
| Reported EPS | 0.87 | 0.73 | 0.57 | 0.63 | 0.54 | 0.35 | 0.41 | 0.31 | 0.33 | 0.14 | 0.38 | 0.29 |
| Estimated EPS | 0.68 | 0.6 | 0.52 | 0.52 | 0.453 | 0.25 | 0.33 | 0.29 | 0.28 | 0.23 | 0.38 | 0.34 |
| Surprise | 0.19 | 0.13 | 0.05 | 0.11 | 0.087 | 0.1 | 0.08 | 0.02 | 0.05 | -0.09 | 0 | -0.05 |
| Surprise Percentage | 27.9412% | 21.6667% | 9.6154% | 21.1538% | 19.2053% | 40% | 24.2424% | 6.8966% | 17.8571% | -39.1304% | 0% | -14.7059% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.6975 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-25 | 2025-12-17 | 2025-09-24 | 2025-06-25 | 2025-03-26 | 2024-12-18 | 2024-09-25 | 2024-06-26 | 2024-03-27 | 2023-12-20 |
| Amount | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 |
Next Dividend Records
| Dividend per share (year): | $0.48 |
| Dividend Yield | 0.92% |
| Next Dividend Date | 2026-03-25 |
| Ex-Dividend Date | 2025-11-26 |
Recent News: PAHC
2026-02-27 02:52:31
A director and 10% owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold $1.1 million worth of Class A Common Stock between February 24 and February 26, 2026. The sales were executed via a pre-arranged Rule 10b5-1 trading plan. This comes as the stock trades near its 52-week high, and an InvestingPro analysis suggests it is overvalued.
2026-02-27 02:51:50
BFI Co., LLC, an entity associated with Phibro Animal Health Corp. (PAHC) President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A common stock between February 24-26, 2026. These open-market transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted in May 2025, with weighted-average sale prices ranging from approximately $51 to $54 per share. The filing indicates some shares are held directly by Jack Bendheim, and others indirectly through BFI Co., LLC.
2026-02-27 01:52:58
A director and a ten percent owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold $1.1 million worth of Class A Common Stock between February 24 and February 26, 2026. The sales were executed through a pre-arranged trading plan as the stock traded near its 52-week high, and InvestingPro analysis suggests the stock is currently overvalued. Despite these insider sales, the company recently reported strong fiscal Q2 2026 results, significantly exceeding revenue and earnings per share forecasts.
2026-02-24 02:52:31
BFI Co. LLC, an entity associated with Phibro Animal Health (PAHC) President and CEO Jack Bendheim, reported pre-planned sales of 14,080 shares of Class A Common Stock. These transactions were executed under a Rule 10b5-1 trading plan at weighted average prices between $50.2568 and $51.9644 per share. Following these sales, BFI Co. LLC holds 22,600 shares, while Jack Bendheim directly holds 16,840 shares.
2026-02-22 02:51:50
An entity linked to Phibro Animal Health's President and CEO, Jack Bendheim, sold 14,080 shares of Class A Common Stock of PAHC through Rule 10b5-1 trading plan. The sales by BFI Co., LLC occurred on February 13 and 18, 2026, at weighted average prices between $51 and $52 per share. Following these transactions, BFI Co., LLC retains 36,680 shares and Bendheim directly holds 16,840 shares.
2026-02-19 03:52:46
Phibro Animal Health (PAHC) reported strong Q2 2026 results with increased sales and net income, along with confident fiscal year 2026 guidance. This improved outlook provides a clearer view of the company's expected profitability, reinforcing its investment narrative amidst ongoing debates about its fair value and long-term margin sustainability. However, investors are cautioned about potential regulatory shifts and the differing analyst views on future performance.
